Brooktree Capital Management Purchases 7,568 Shares of Cardlytics, Inc. (NASDAQ:CDLX)

Brooktree Capital Management lifted its holdings in shares of Cardlytics, Inc. (NASDAQ:CDLX) by 4.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 175,210 shares of the company’s stock after buying an additional 7,568 shares during the quarter. Cardlytics comprises 0.5% of Brooktree Capital Management’s investment portfolio, making the stock its 21st biggest position. Brooktree Capital Management’s holdings in Cardlytics were worth $650,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of CDLX. Intech Investment Management LLC purchased a new stake in shares of Cardlytics during the third quarter worth $47,000. Charles Schwab Investment Management Inc. lifted its holdings in Cardlytics by 3.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 390,343 shares of the company’s stock worth $1,249,000 after purchasing an additional 11,388 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in Cardlytics during the 3rd quarter worth about $153,000. BNP Paribas Financial Markets grew its holdings in Cardlytics by 32.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 19,745 shares of the company’s stock valued at $63,000 after buying an additional 4,796 shares in the last quarter. Finally, Atom Investors LP bought a new stake in shares of Cardlytics during the third quarter valued at about $33,000. 68.10% of the stock is owned by institutional investors.

Cardlytics Stock Performance

Cardlytics stock opened at $2.38 on Tuesday. Cardlytics, Inc. has a fifty-two week low of $1.77 and a fifty-two week high of $20.52. The company has a debt-to-equity ratio of 2.40, a quick ratio of 1.18 and a current ratio of 1.18. The stock has a market cap of $120.96 million, a P/E ratio of -0.39 and a beta of 1.62. The firm’s fifty day moving average price is $2.97 and its 200-day moving average price is $3.48.

Wall Street Analyst Weigh In

Several brokerages recently commented on CDLX. Evercore ISI reduced their price objective on shares of Cardlytics from $4.00 to $3.00 and set an “in-line” rating for the company in a research note on Thursday, March 13th. Lake Street Capital decreased their price target on shares of Cardlytics from $5.00 to $3.00 and set a “hold” rating on the stock in a report on Thursday, March 13th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Cardlytics in a research note on Thursday, March 13th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $6.42.

Insider Buying and Selling at Cardlytics

In related news, CEO Amit Gupta sold 15,160 shares of the firm’s stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $3.92, for a total transaction of $59,427.20. Following the transaction, the chief executive officer now directly owns 215,494 shares of the company’s stock, valued at approximately $844,736.48. This trade represents a 6.57 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Alexis Desieno sold 24,778 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $3.40, for a total value of $84,245.20. Following the completion of the sale, the chief financial officer now directly owns 140,948 shares of the company’s stock, valued at approximately $479,223.20. This represents a 14.95 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 111,454 shares of company stock worth $391,864 over the last 90 days. Corporate insiders own 4.40% of the company’s stock.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.